Key result
Revascularization for stable CAD shows uncertain benefit for reducing death or alleviating angina.
Why the study?
Recent randomized controlled trials have challenged traditional teachings regarding revascularization procedures for patients with stable coronary artery disease.
Do revascularisation procedures reduce the risk of death or alleviate angina in patients with stable coronary artery disease?
Do revascularisation procedures reduce the risk of death or alleviate angina in patients with stable coronary artery disease?
This review highlights how recent major trials like ISCHEMIA and ORBITA challenge the traditional reliance on revascularisation for managing stable coronary artery disease.
Supports deferring routine revascularization for stable CAD; leaves open individualized decisions pending targeted trials.
Recent randomised controlled trials, such as ISCHEMIA and ORBITA, have overturned most of what we were taught in medical school about hospital procedures considered necessary for patients with stable coronary artery disease. In this article, we discuss what these trials mean for physicians and patients considering revascularisation procedures with the hope of reducing the risk of death or alleviating angina.
No takes yet. Share an insight, caveat, or question.
Nowbar et al. (2021) conducted a review in stable coronary artery disease. revascularisation procedures was evaluated. Revascularization procedures for stable coronary artery disease have been challenged by recent trials regarding their necessity for reducing death or alleviating angina.